Metraipolis › archive › dc_79228b73170b
Pregnancy outcomes of patients with retained products of conception following miscarriage treated with relugolix, an oral gonadotropin-releasing hormone… — Europe PMC PMID:41658607
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41658607
- DOI
- 10.3389/fmed.2026.1704529
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-06T13:15:56.473Z
- SHA-256 of the archived text
67147cf0f3830a16ab9db3a403fb52a9b97c66a3389d889c74e577a329e8dc38- Stable URL of this page
https://metraipolis.com/documento/dc_79228b73170b
How to cite
Pregnancy outcomes of patients with retained products of conception following miscarriage treated with relugolix, an oral gonadotropin-releasing hormone… — Europe PMC PMID:41658607 — Europe PMC (en), https://europepmc.org/article/MED/41658607 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_79228b73170b (Metraipolis archive dc_79228b73170b, sha256 67147cf0f3830a16ab9db3a403fb52a9b97c66a3389d889c74e577a329e8dc38)
BibTeX
@misc{dc79228b73170b,
title = {Pregnancy outcomes of patients with retained products of conception following miscarriage treated with relugolix, an oral gonadotropin-releasing hormone… — Europe PMC PMID:41658607},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41658607},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_79228b73170b; sha256 67147cf0f3830a16ab9db3a403fb52a9b97c66a3389d889c74e577a329e8dc38},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41658607. Agents can read the archived copy with the MCP tool read_document.